argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting ADHERE data presentation will highlight first potential innovation for CIDP patients in 30

argenx Delivers on Promise to Transform Patient

Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

ADHERE data presentation will highlight first

potential innovation for CIDP patients in 30 years

reflect real-world value and consistent efficacy and safety profile associated with long-term use of VYVGART

and VYVGART Hytrulo in gMG patients

March 7, 2024, 10:01 pm CET

the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives

of people suffering from severe autoimmune diseases, today announced that eight abstracts, including two oral presentations, featuring

clinical trial and real-world data for VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)

in rare autoimmune diseases will be presented at the American Academy of Neurology (AAN) Annual Meeting, taking place in Denver, CO from

"We are opening a new chapter for the VYVGART

portfolio," said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx. "While VYVGART continues to reach more gMG patients

globally, we are also striving to bring meaningful benefits to people living with CIDP - a community which has been awaiting innovation

for 30 years. We are excited to present a broad set of data at AAN this year that collectively demonstrate how we are delivering on our

promise to transform patients' lives with innovative treatments."

Transforming Autoimmunity by Targeting FcRn

Findings from the ADHERE study of VYVGART Hytrulo

in chronic inflammatory demyelinating polyneuropathy (CIDP) will be presented for the first time in an oral presentation during the Clinical

Trials Plenary Session, taking place on Tuesday, April 16, 2024. These positive data from the ADHERE study have been submitted to the

FDA for potential approval of VYVGART Hytrulo in CIDP with a PDUFA target action date of June 21, 2024.

In addition to the full ADHERE data, the AAN presentations

will highlight clinical trial and real-world data showcasing the broad opportunity with VYVGART, a first-in-class neonatal FC receptor

(FcRn) inhibitor, and VYVGART Hytrulo, to deliver significant value to the generalized myasthenia gravis (gMG) patient community by driving

consistent and repeatable improvements across patient subtypes, a favorable and predictable safety profile, and the ability to individualize

treatment across both intravenous and subcutaneous administration and dosing schedules.

Details for oral and poster presentations at

More information on the program is available at AAN.

See Important Safety Information below, full United

States Prescribing Information for VYVGART and full Prescribing Information for VYVGART Hytrulo for additional information.

What is VYVGART (efgartigimod

alfa-fcab) for intravenous (IV) infusion and what is VYVGART HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous

VYVGART and VYVGART HYTRULO are both prescription

medicines, each used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout

the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

Do not use VYVGART if you have a serious allergy

to efgartigimod alfa or any of the other ingredients in VYVGART. Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod

alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART and VYVGART HYTRULO can cause serious allergic reactions

and a decrease in blood pressure leading to fainting

VYVGART and VYVGART HYTRULO may cause serious

side effects, including:

VYVGART and VYVGART HYTRULO may increase the risk

of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections.

Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus,

wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.

Allergic Reactions (hypersensitivity reactions)

VYVGART and VYVGART HYTRULO can cause allergic

reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART

HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with

efgartigimod alfa-fcab.

Infusion-Related Reactions

VYVGART and VYVGART HYTRULO can cause infusion-related

reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and

chest, abdominal, and back pain

Tell your doctor if you have signs or symptoms

of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART or VYVGART HYTRULO

treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms

of a serious allergic reaction.

Before taking VYVGART or VYVGART HYTRULO, tell

What are the common side effects of VYVGART

and VYVGART HYTRULO?

The most common side effects in efgartigimod-alfa-fcab-treated

patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO

are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of

VYVGART and VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug

Administration at 1-800-FDA-1088.

see the full Prescribing Information for VYVGART and the full Prescribing

Information for VYVGART HYTRULO.

Generalized Myasthenia Gravis

myasthenia gravis (gMG) is a rare and chronic autoimmune disease where IgG autoantibodies disrupt communication between nerves and muscles,

causing debilitating and potentially life-threatening muscle weakness. Approximately 85% of people with MG progress to gMG within 24 months,1

where muscles throughout the body may be affected. Patients with confirmed AChR antibodies account for approximately 85% of the total

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

inflammatory demyelinating polyneuropathy (CIDP) is a rare and serious autoimmune disease of the peripheral nervous system. Although confirmation

of disease pathophysiology is still emerging, there is increasing evidence that IgG antibodies play a key role in the damage to the peripheral

nerves. People with CIDP experience fatigue, muscle weakness and a loss of feeling in their arms and legs that can get worse over time

or may come and go. These symptoms can significantly impair a person's ability to function in their daily lives. Without treatment, one-third

of people living with CIDP will need a wheelchair.

is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies.

It is the first approved FcRn blocker in the United States, EU and China for the treatment of adults with generalized myasthenia gravis

(gMG) who are anti- acetylcholine receptor (AChR) antibody positive and in Japan for the treatment of adults with gMG who do not have

sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

Hytrulo is a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment marketed for intravenous use as VYVGART ,

and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE drug delivery technology to facilitate subcutaneous

injection delivery of biologics. In binding to the neonatal Fc receptor (FcRn), VYVGART Hytrulo results in the reduction of circulating

IgG. It is the first-and-only approved FcRn blocker administered by subcutaneous injection.

Hytrulo is the proprietary name in the U.S. for subcutaneous efgartigimod alfa and recombinant human hyaluronidase PH20. It may be marketed

under different proprietary names following approval in other regions.

argenx is a global immunology company committed

to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology

Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.

argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the

UK, Canada and China. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage

experimental medicines within its therapeutic franchises. For more information,

visit www.argenx.com and

Forward-Looking Statements

contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking